Obesity

Pfizer’s Once‑Monthly GLP‑1 Shows Strong Weight Loss but Raises Dosing‑Safety Questions

Mid‑stage ADA data led Pfizer to plan slower dose escalation and an expanded Phase 3 program to test monthly dosing after trials showed meaningful weight loss with clustered gastrointestinal side effects.